NRx Pharmaceuticals, Inc.
NRXP
$3.87
-$0.46-10.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.56% | 75.93% | 16.56% | -35.40% | -30.75% |
| Depreciation & Amortization | -- | 4,100.00% | 1,200.00% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.22% | 53.47% | 44.28% | -47.09% | -37.53% |
| Operating Income | -26.71% | -26.42% | -36.27% | 47.09% | 37.53% |
| Income Before Tax | 74.06% | 103.97% | -262.91% | -122.63% | 15.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.06% | 103.97% | -262.91% | -122.63% | 15.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.06% | 103.97% | -262.91% | -122.63% | 15.56% |
| EBIT | -26.71% | -26.42% | -36.27% | 47.09% | 37.53% |
| EBITDA | -25.07% | -25.30% | -36.05% | 47.10% | 37.54% |
| EPS Basic | 86.84% | 101.67% | -79.11% | -30.57% | 54.45% |
| Normalized Basic EPS | 83.59% | 76.52% | 25.71% | 10.49% | 61.36% |
| EPS Diluted | 86.84% | 101.67% | -79.11% | -30.57% | 54.45% |
| Normalized Diluted EPS | 83.59% | 76.52% | 25.71% | 10.49% | 61.36% |
| Average Basic Shares Outstanding | 96.98% | 136.39% | 102.59% | 70.52% | 85.38% |
| Average Diluted Shares Outstanding | 96.98% | 136.39% | 102.59% | 70.52% | 85.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |